Can a psychedelic experience lasting less than an hour provide lasting relief for depression that has resisted conventional medications? In a randomized clinical trial published in the Journal of the American Medical Association (JAMA) on October 26, 2026, researchers found that a single intranasal dose of mebufotenin benzoate produced rapid, clinically meaningful reductions in depression severity through eight weeks of follow-up. Crucially, roughly 80 percent of participants met clinical criteria for discharge within two hours of treatment.
Major depressive disorder affects an estimated 280 million people worldwide, according to the World Health Organization. While standard oral antidepressants like SSRIs help many individuals, clinical guidelines from the National Institute of Mental Health note that approximately one in three patients experiences treatment-resistant depression—defined as persistent symptoms despite two or more trials of standard therapies of adequate dose and duration. While first-generation psychedelic therapies such as psilocybin show promise, their six- to eight-hour duration creates major staffing and cost barriers for clinics. The new JAMA trial evaluated whether an ultrashort-acting compound could deliver comparable benefits without monopolizing clinical resources.
What Is Mebufotenin and How Does It Act on the Brain?
Mebufotenin, biochemically known as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), is a naturally occurring tryptamine alkaloid found in certain plants and the venom of the Sonoran Desert toad (Incilius alvarius). Unlike psilocybin or LSD, which primarily stimulate 5-HT2A serotonin receptors, mebufotenin acts as a potent dual agonist at both 5-HT1A and 5-HT2A receptor subtypes.
Serotonin 1A receptor activation triggers inhibitory signaling across hyperactive regions of the default mode network (DMN)—the brain network tied to rigid, negative rumination in depression. Concurrently, 5-HT2A receptor stimulation promotes brain-derived neurotrophic factor (BDNF), initiating synaptogenesis and cellular dendritic remodeling. Because mebufotenin undergoes rapid clearance by monoamine oxidase A, its acute effects peak within ten minutes and subside within 30 to 45 minutes, allowing a rapid return to lucidity.
Inside the Phase 2b JAMA Clinical Trial
The double-blind, randomized trial was conducted across 38 academic and medical research sites in the United States, Australia, and Europe between September 2023 and April 2025. Led by psychiatrist Dr. David Feifel and colleagues, the trial enrolled 193 adults aged 18 to 75 years with moderate-to-severe major depressive disorder who had failed two to five prior antidepressant courses during their current episode.
Following medication washout, participants were randomized to receive a single intranasal spray alongside standardized psychological support:
- 12 mg mebufotenin benzoate (n = 73): High-dose therapeutic intervention
- 8 mg mebufotenin benzoate (n = 46): Intermediate-dose therapeutic intervention
- 0.3 mg mebufotenin benzoate (n = 74): Subperceptual low-dose active comparator to preserve study blinding
The primary outcome was total score change on the Montgomery-Åsberg Depression Rating Scale (MADRS; 0–60 scale, higher scores reflect more severe illness) from baseline to Day 29.
Primary Findings: Rapid and Durable Antidepressant Action
The trial met its primary efficacy endpoint with strong statistical significance. Patients receiving the 12-mg dose experienced a mean MADRS reduction of 11.1 points from baseline to Day 29, compared to 5.5 points in the 0.3-mg comparator group—an adjusted mean difference of −5.3 points (95% CI, −8.9 to −1.8; P = .003). The 8-mg cohort demonstrated an average reduction of 12.5 points, achieving a mean difference of −6.2 points (95% CI, −10.2 to −2.1; P = .003) versus control.
Clinical response (≥50% MADRS reduction) at Day 29 reached 35 percent in the 8-mg arm and 34 percent in the 12-mg arm, compared with 12 percent in controls. Remission (MADRS score ≤10) occurred in 26 percent taking 8 mg and 18 percent taking 12 mg, versus 8 percent in controls. Antidepressant benefits emerged within 48 hours and remained statistically separated from control across the entire 57-day (eight-week) blinded assessment period.
Clinical Logistics: Comparing Practical Treatment Footprints
A key clinical finding was the timeline of discharge readiness. In conventional psilocybin protocols, patients require two specialized clinicians for six to eight continuous hours. In the JAMA trial, discharge readiness was assessed starting at 90 minutes post-dose. Overall, 85 percent of participants in the 8-mg group and 78 percent in the 12-mg group met all physiological and cognitive safety criteria for discharge within two hours.
| Therapeutic Agent | Receptor Targets | Acute Duration | Discharge Readiness | Development Stage |
|---|---|---|---|---|
| Mebufotenin Benzoate (Nasal Spray) | 5-HT1A & 5-HT2A dual agonist | 15–45 minutes | 78%–85% within 2 hours | Phase 2b completed (JAMA 2026) |
| Psilocybin (Oral Capsule) | 5-HT2A agonist | 4–6 hours | 6–8 hours monitoring | Phase 3 clinical trials |
| Esketamine (Nasal Spray) | NMDA receptor antagonist | 40–60 minutes | 2 hours mandatory observation | FDA approved (requires repeat visits) |
Source: Comparative pharmacological synthesis adapted from Feifel et al., JAMA (2026) and APA clinical reports.
Safety Profile and Study Limitations
Safety monitoring showed mebufotenin was generally well tolerated. Adverse events occurred in 76 percent of the 8-mg group, 85 percent of the 12-mg group, and 73 percent of controls; 99.7 percent of reported events were mild or moderate. The most frequent complaints were transient headache, mild nausea, and nasal irritation, resolving within hours. There were no treatment-related serious adverse events or prolonged psychotic symptoms.
Several scientific limitations warrant careful interpretation:
- Phase 2b Design: While 193 participants represents a solid Phase 2 sample, larger Phase 3 trials are required to confirm efficacy and monitor long-term safety before regulatory approval.
- Blinding Challenges: Because active doses produce noticeable perceptual changes, functional unblinding among patients and raters remains an inherent challenge despite the active low-dose comparator.
- Psychological Support Framework: The medication was delivered alongside preparatory and integration counseling; outcomes cannot be separated from this supportive clinical setting.
- Investigational Status: Mebufotenin is an investigational drug. It is not an approved treatment, and illicit sourcing carries severe legal and physical risks.
Standard guidelines from the American Psychiatric Association emphasize that individuals experiencing persistent depressive symptoms should consult licensed psychiatric professionals to explore evidence-based therapies, lifestyle adjustments, and approved pharmacotherapies.
Sources and Further Reading
- Feifel D, Seynaeve M, Cubala WJ, et al. Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. Published online October 26, 2026. https://doi.org/10.1001/jama.2026.18380 (PMCID: PMC13711228)
- National Institute of Mental Health. Depression: Overview, Signs, and Treatment Options. https://www.nimh.nih.gov/health/topics/depression
- World Health Organization. Depressive Disorder (Depression) Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/depression
- American Psychiatric Association. What Is Depression? Clinical Diagnostic Guidelines and Standards of Care. https://www.psychiatry.org/patients-families/depression/what-is-depression
Related Reading
- Inflammation and Depression: New Immune-Targeted Research
- Exercise for Depression: What Research Shows Works Best
- Silexan for Anxiety and Sleep: What the Science Shows
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.